Abbott India Limited announced a strategic collaboration with Novo Nordisk India to commercialize Extensior®, a second brand for semaglutide (Ozempic®), for advanced type 2 diabetes management. This partnership leverages Novo Nordisk’s GLP-1 expertise and Abbott’s distribution network to expand access to this evidence-based therapy across India. Extensior® offers powerful HbA1c reduction, weight-loss benefits, and proven cardiovascular/kidney risk reduction.
Abbott and Novo Nordisk Partner to Launch Extensior®
On February 27, 2026, Abbott India Limited disclosed a strategic collaboration with Novo Nordisk India to commercialize Extensior®, a brand extension of semaglutide (Ozempic®), aimed at broadening access for people managing advanced type 2 diabetes in India.
This partnership unites Novo Nordisk’s global leadership in GLP-1 therapies with Abbott’s extensive Indian distribution footprint, ensuring more patients benefit from modern, evidence-based treatments.
Key Benefits of Extensior® (Semaglutide)
Extensior® is approved as an adjunct to diet and exercise for adults with type 2 diabetes. The active molecule, semaglutide, is recognized for offering a broad spectrum of benefits, including:
- Powerful HbA1c reduction.
- Compelling weight-loss benefits.
- Proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes.
Semaglutide has been supported by over 44+ robust clinical trials and has over 49 million patient years* of use globally across all semaglutide products.
Expanding Access in a High-Burden Market
Kartik Rajendran, Managing Director of Abbott India Limited, stated that the launch builds upon Abbott’s commitment to holistic diabetes management, encompassing medicines, diagnostics, and nutrition. Extensior® is expected to be available to Indian patients soon.
Vikrant Shrotriya, Managing Director of Novo Nordisk India, emphasized that the collaboration will make this innovative molecule accessible to a greater number of people. India currently faces a significant diabetes burden, with over 100 million individuals living with diabetes, projected to surge to over 150 million by 2050, highlighting the urgent need for expanded access to effective treatments.
Product Details
Extensior®/Ozempic® (semaglutide injection) will be available in the FlexTouch® Pen, an easy-to-use, once-weekly device providing precise dosing in 0.25 mg, 0.5 mg, and 1 mg strengths. The active ingredient is 94% homogenous to the naturally-occurring GLP-1 in the human body, and in 2025, semaglutide was added to the WHO’s essential medicines list.
Source: BSE
